Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody TherapyRajat Bannerji, Carrie Brownstein, Ranjana H. Advani et al.|Blood|2016Cited by 19